logo-loader
AzurRx BioPharma Inc

AzurRx BioPharma reports positive results in its Phase 2a trial of pancreatitis drug

MS1819-SD was developed to treat exocrine pancreatic insufficiency caused by chronic pancreatitis

Scientist
The drug may also be able to be applied to the treatment of cystic fibrosis

AzurRx BioPharma Inc (NASDAQ:AZRX) announced a successful Phase 2a trial study of its pancreatitis drug.

MS1819-SD is designed to treat exocrine pancreatic insufficiency caused by chronic pancreatitis, a disease characterized by inflammation of the pancreas.

READ: Trevena shares pop on successful completion of Phase 1 study of acute migraine treatment

Initial data from the study shows a “very strong safety and efficacy profile”, according to the company’s press statement.

The Brooklyn-based biopharma will look into applying the drug to the treatment of cystic fibrosis as well.

“Based on these data, we believe we have the basis for initiating a Phase IIb trial of MS1819 in cystic fibrosis patients in the fall of 2018,” said Chief Medical Officer James Pennington in a statement.

The biopharma specializes in the development of non-systemic, recombinant therapies for gastrointestinal diseases. While MS1819 is its lead drug candidate, it is also conducting early-stage research into the prevention of hospital-acquired infections.

Shares jumped nearly 8% to US$3.16 in Friday morning trading.

Quick facts: AzurRx BioPharma Inc

Price: $1.21

Market: NASDAQ
Market Cap: $31.59 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Gatling Exploration is well funded and increasing their...

Gatling Exploration (CVE: GTR) President and CEO Nav Dhaliwal sat down with Steve Darling from Proactive Vancouver with news Gatling has increased their drill program to 35,000 metres. Dhaliwal talked about where they are targeting with this new beefed-up program.  Dhaliwal also told...

3 hours, 26 minutes ago

2 min read